Stem cell therapy for regenerating intervertebral discs - 16/07/2020

Ulm’s simulator has Europe’s back

Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

Qualitative soil fertiliser - 10/07/2020

How natural cycles can be closed with wood ash

Recycled material instead of waste: wood ash is good for soil and plants - if the quality is right. The German Federal Quality Association for Food Ash ensures reliable wood ash standards with its certifications. The RAL-Dünger label for fertilisers provides the necessary certification for natural wood ashes to be used in the circular economy.

Review article (new edition) - 08/07/2020

Immunology – at the forefront of medical progress

Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

Affimed GmbH - 01/07/2020

"Innate cell engager" fighting against cancer

In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

rezemo GmbH - 26/06/2020

Coffee capsules: wood instead of aluminium

In Germany alone, around three billion disposable coffee capsules made of aluminium and plastic are sold every year. This creates a gigantic waste problem, as only a small proportion of the capsules can be recycled. Fully compostable wooden coffee capsules might be a solution to this problem. The capsules have been developed by a start-up company called rezemo, which also has other biobased packaging solutions in the pipeline.

SICOS BW GmbH - 18/06/2020

High-performance computing and data analytics to combat coronavirus

In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.

Perspectives of methane as energy source - 18/06/2020

New technologies for using biogas as a balancing energy

The microorganisms in biogas plants do a great job biologically converting CO₂ and hydrogen, which are primary fermentation products, into methane. Biomethane has a great future as an energy source. Scientists at the University of Hohenheim are investigating new ways to produce and use biomethane.

Innovations in the field of endoscopy - 08/06/2020

Gastroscopies with pill cameras

A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

Vaccine development - 02/06/2020

CureVac as a pioneer of mRNA technology - what is behind the novel COVID-19 vaccine?

All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

Degradable biopolymers - 29/05/2020

Bioplastics make wood cycles more sustainable

Innovative technologies and bacteria can transform wood residues into sustainable bioplastic packaging. Before bioplastics are broken down into CO2 and water in an environmentally friendly way, they can thus lead lives as products in the cosmetics industry, for example.

Translational oncology - 26/05/2020

Translation: driver of cancer medicine

The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

Material research - 25/05/2020

Reaching up into weightlessness – a start-up that enables commercial research experiments in space

Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.

The “Rhizo-Lentil" EIP-AGRI project - 20/05/2020

NovoCarbo turns plant waste into biochar

NovoCarbo GmbH produces biochar from plant residues such as wood chips, nutshells and manure. Different feedstocks, and the way these materials are processed, create biochars with different properties. This makes biochar suitable for different uses, including as a soil conditioner, in biogas plants or as bedding for stables and cowsheds. The Rhizo-Linse project is currently investigating whether biochar is also suitable as inoculant carrier for…

Trenzyme GmbH - 20/05/2020

The SARS-CoV spike protein and its receptor

The SARS-CoV-2 coronavirus uses a spike protein to bind to the ACE2 receptor on the cell surfaces of lung tissue. Additional cofactors are needed to allow the virus genome to penetrate human cells and multiply. Knowing these relationships can help understand the course of the infection and develop counterstrategies. To this end, the Constance-based company Trenzyme has produced a recombinant spike protein to support coronavirus research.

Heidelberg Technology Park - 05/05/2020

Start-up support for life sciences companies

How can scientists turn their know-how into marketable products and services and thereby provide society with real added value? In addition to solid financing, start-up companies need a suitable infrastructure and a dense network of partners for exchanging expertise to help them get off to a good start when it comes to setting up a business. The Heidelberg Technology Park offers company founders in the life sciences exactly these success factors.

Dossier - 28/04/2020

Sustainable bioenergy

Biomass from forestry and agriculture along with residues from industry and households can contribute to our energy and raw material shift. Sustainable, regenerative biomass-based energy can become part of the energy mix of the future within the framework of a bioeconomy.

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020

A rapid pyrogen test: the human immune system as model

Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.

Urban agriculture - 23/04/2020

alphabeet – the green-fingered smartphone

Given the challenges faced by modern agriculture, it is vital to raise people’s awareness of how to change their approach to food. The founders of the Stuttgart-based start-up company farmee GmbH see urban agriculture as the key to making this change possible. The company has developed “alphabeet”, an app designed to encourage consumers to produce their own food. After all, only those combining knowledge and practical experience can be expected…

Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

Biosensors - 09/04/2020

Sensors for the bioeconomy

Sensor networks are one of the keys to achieving digitalisation of the bioeconomy. Sensor networks are on the way to becoming important analysis and control instruments for energy-efficient and sustainable material cycles. Dieter Hertweck, Professor of Business Information Systems at Reutlingen University of Applied Sciences, shows what is already possible in digital agriculture and waste recycling and what is feasible for the future.

Bioinspired technologies - 03/04/2020

Diagnostics with molecular scissors – is this also possible for on-site COVID-19 tests?

The CRISPR-Cas gene-editing technology is one of the most important developments in molecular biology in recent years. It utilises molecular scissors with which nucleic acids can be cut and edited almost arbitrarily. Researchers in Freiburg, Germany have now successfully used the technology for diagnostic purposes. They are currently working intensively on expanding the system to enable it to detect genome sequences of the novel SARS-CoV-2 virus.

Multiple sclerosis - 12/03/2020

Direct application of biopharmaceuticals through the nose into the brain

There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.